A finequestion

Cerimele, Chris
October 2007
ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p13
Trade Publication
The article focuses on common concerns among outsourcers of fine chemicals, and how does merger and acquisition (M&A) activity relate to those issues. According to Contract Pharma's 2006 Annual Outsourcing Survey, the top five factors include quality, timeliness, confidentiality, good manufacturing practice capability and relationship. According to the author, pharmatech firms have a keen interest in the impact M&A could have on the stability of their critical fine chemical supplier base.


Related Articles

  • Going global. Kovac, Matt; O'Driscoll, Cath // ICIS Chemical Business;7/31/2006, Vol. 1 Issue 30, p26 

    The article focuses on cross-border mergers and acquisitions by Indian chemical companies. In 2005, Indian companies made 103 cross-border acquisitions. This trend of overseas acquisitions is said to have been caused by India's competition with western nations in areas such as active ingredients...

  • Custom Synthesis and Custom Chemicals. Polastro, Enrico T. // Pharmaceutical Technology;Aug2006 Supplement, Vol. 30, p42 

    The chemical synthesis industry is a dynamic, highly segmented, and growing component of the overall outsourcing business. It has a distinctive service platform and customer base compared with chemical suppliers, thus requiring a clear understanding of key success factors, expectations from...

  • Drug Industry Flux Proves Good Therapy for Suppliers. Ramesh, Deepti // Chemical Week;1/19/2009, Vol. 171 Issue 2, p19 

    The article discusses the market challenges and opportunities facing fine chemicals and contract manufacturing service suppliers of major drug companies. Suppliers expect increased outsourcing opportunities as well as plant sale offerings with long-term supply contracts. Industry executives say...

  • INDIAN SCENE.  // Chemical Business;May2001, Vol. 15 Issue 5, p28 

    Presents news briefs on the Indian pharmaceutical and chemical sectors as of May 2001. Acquisition of the manufacturing facilities of Uniloids Ltd. by AVRA Laboratories; Expected market growth of the pharmaceutical industry; Rejection of the toll manufacturing agreement proposed by Pfizer Corp.

  • Fine Chem Manufacturers To Strive for Critical Mass. Jarvis, Lisa // Chemical Market Reporter;01/01/2001, Vol. 259 Issue 1, p4 

    Focuses on the mergers and acquisitions (M&A) activity in the fine chemicals industry in the United States. What prompted mergers among pharmaceutical industry; Factors forcing some traditional chemical companies to withdraw from the pharmaceutical business; Fine chemical companies whose M&A is...

  • FTC, Department of Justice to Speed Antitrust Reviews.  // Chemical Week;3/13/2002, Vol. 164 Issue 11, p5 

    Reports the division of roles in federal reviews of proposed business mergers by the U.S. Federal Trade Commission (FTC) and the antitrust division of Department of Justice (DOJ). Authority of FTC on the chemical and pharmaceutical industries; Focus of DOJ on the high-technology and...

  • Fine Chemicals Producers Need to Look Beyond Size. Jarvis, Lisa // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p8 

    Focuses on the effects on fine chemicals producers of the productivity issues facing the pharmaceutical industry as of October 22, 2001. Problems forcing the pharmaceutical industry to reexamine its operating model; Views of consultant Peter Pollak on mergers and acquisitions in the...

  • Reshaping CMC Development Services. Miller, Jim // Pharmaceutical Technology;Sep2005, Vol. 29 Issue 9, p102 

    Focuses on the impact of the lack of acquisition activity in the pharmaceutical sector on chemistry, manufacturing and control development services in the U.S. Changes in the way pharmaceutical companies buy contract services; Plan of pharmaceutical firms to reduce the number of suppliers they...

  • pharceuticals & fine chemicals.  // Chemical Week;7/5/2006, Vol. 168 Issue 23, p22 

    This article presents news briefs on the pharmaceuticals and fine chemicals sector of the chemical industry. Lannett has signed an agreement to outsource manufacturing of two unspecified drugs to contract manufacturer Olive Healthcare based in Mumbai, India. Meanwhile, Generic drugs firm Barr...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics